Kadmon’s ROCKstar Is Rising On GvHD Therapy Data
Belumosudil Shines In Study
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.
You may also be interested in...
Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.
A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.